Received Aug 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HBHEPB | HIB + HEP B (COMVAX) | MERCK & CO. INC. | 3 | Y005366 | — |
| HBHEPB | HIB + HEP B (COMVAX) | MERCK & CO. INC. | 2 | — | — |
| HBHEPB | HIB + HEP B (COMVAX) | MERCK & CO. INC. | 1 | — | — |
patient has not reported any symptoms; inadvertently administering a dose of PEDVAX HIB to a 13 year old patient who was scheduled to received a meningitis B BESTRO vaccine; This spontaneous report was received from a medical assistant and refers to a 13-year-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On unspecified dates (discrepancy, reported as 10-NOV-2005 and 05-MAR-2007), the patient was vaccinated with 1st and 2nd dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAX HIB) suspension for injection, administered for prophylaxis (dose, route of administration, anatomical location, lot# and expiry date were not reported). On 30-JUL-2025, the patient was inadvertently vaccinated with 3rd dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAX HIB) suspension for injection, lot #Y005366, expiration date: 05-NOV-2026, administered for prophylaxis (dose, route of administration and anatomical location were not reported) instead of scheduled meningococcal vaccine b rfhbp/nada/nhba omv (BEXSERO) (reported as "meningitis B BESTRO vaccine") (Wrong product administered). The patient had not reported any symptoms. Lot# (Dose 1 and 2) is being requested and will be submitted if received.